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http://dx.doi.org/10.1016/j.ccell.2016.09.001SUMMARYLung squamous cell carcinoma (LSCC) is a devastating malignancy with no effective treatments, due to its
complex genomic profile. Therefore, preclinical models mimicking its salient features are urgently needed.
Here we describe mouse models bearing various combinations of genetic lesions predominantly found in
human LSCC. We show that SOX2 but not FGFR1 overexpression in tracheobronchial basal cells combined
with Cdkn2ab and Pten loss results in LSCC closely resembling the human counterpart. Interestingly,
Sox2;Pten;Cdkn2ab mice develop LSCC with a more peripheral location when Club or Alveolar type 2
(AT2) cells are targeted. Our model highlights the essential role of SOX2 in commanding the squamous
cell fate from different cells of origin and represents an invaluable tool for developing better intervention
strategies.INTRODUCTION
Lung cancer is the leading cause of cancer-related deaths
worldwide, with more than one-quarter (27%) of deaths among
both men and women (Siegel et al., 2015). Non-small cell lung
cancer, which includes adenocarcinoma (ADC), squamous cell
carcinoma (SCC), and large cell carcinoma, is the predominant
histological type, accounting for more than 80% of cases.
More than 50%of cases present amixed histological phenotype,
indicative of the marked heterogeneity in lung cancer (Travis,
2002; Walker, 2008). With more than 400,000 deaths worldwide
each year (Cancer Genome Atlas Research Network, 2012; Je-Significance
LSCC is a devastating disease for which more effective treatm
reproducing its salient features are of pivotal importance. W
basal cells serve as a highly effective cell of origin of diverse lu
sion drives Pten- andCdkn2ab-deficient heterogeneous tumor
in human LSCC. We show that multiple cell types in lung can g
and peripheral lung.
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ranking second only to ADC. These two major subtypes are
associated with distinct molecular abnormalities (Cancer
Genome Atlas Research Network, 2012; Cancer Genome Atlas
Research Network, 2014) and are thought to have distinct cells
of origin (Giangreco et al., 2007; Sutherland and Berns, 2010;
Sutherland et al., 2011). The knowledge of the molecular
mechanisms driving lung ADC (LADC) has resulted in targeted
treatments, not yet found for lung SCC (LSCC).
In the comprehensive analysis of human LSCC recently re-
ported by The Cancer Genome Atlas (TCGA) network, LSCC
samples displayed a large variety of DNA alterations clusteredents are urgently needed. Therefore, representative models
e show that Pten- and Cdkn2ab-deficient tracheobronchial
ng tumors. We show that SOX2, but not FGFR1, overexpres-
s into LSCC, in line with the frequent overexpression of SOX2
ive rise to LSCC, with different growth patterns in the central
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in four well-defined pathways: squamous differentiation path-
way (SOX2, NOTCH), phosphoinositol 3-kinase (PI3K) pathway
(FGFR1, PTEN), cell-cycle regulation (CDKN2A, RB1, TP53),
and oxidative stress response (CUL3, KEAP1, NFE2L2) (Cancer
Genome Atlas Research Network, 2012). The higher molecular
complexity and the absence of predominant actionable driver al-
terations (Bass et al., 2009; Cancer Genome Atlas Research
Network, 2012; Weiss et al., 2010) have hampered the develop-
ment of preclinical models that mimic human LSCC at both ge-
notype and phenotype levels. Single oncogenic alterations intro-
duced in the mouse failed to drive the development of LSCC
while mostly promoting LADC (Lu et al., 2010; Malkoski et al.,
2014).
The first model of LSCC morphologically resembling the hu-
man counterpart is based on the deregulation of IKKa, a protein
kinase, whose reduced activity was already associated with
SCC development in skin and oral cavity but rarely in lung (Liu
et al., 2012). A dominant negative mutant form of IKKa causes
SCC in a variety of tissues but at a very low frequency in lung
(Xiao et al., 2013). Prolonged survival by restricting the dominant
negative effect to the lungs did, however, increase the frequency
of LSCC. Two conditional models recently described are based
on Lkb1 loss, which is found to be inactivated in approximately
2% of human LSCC (Cancer Genome Atlas Research Network,
2012; Travis, 2002). In one model, which combines Lkb1 and
Pten deletion, mice develop LSCC morphologically resembling
the human counterpart with a latency of 40–50 weeks (Xu
et al., 2014). In the other model, mice harboring a conditional
deletion of Lkb1 develop LSCC, and in a few cases LADC,
following intranasal infection with a lentivirus carrying SOX2
and PGK-Cre-recombinase; the latency is shorter (6–10 months)
due to the concomitant overexpression of SOX2, and the pene-
trance of tumor formation is 40% (Mukhopadhyay et al., 2014).
Although the combination of genetic alterations is critical for
the tumor phenotype, increasing evidence also points to the
cell of origin as an important factor in determining tumor charac-
teristics (Sutherland et al., 2011, 2014; Visvader, 2011). LSCC
was thought to mainly arise in the upper airways, but according
to recent reports peripheral LSCC is becoming as frequent as the
central type (Funai et al., 2003; Hayashi et al., 2013; Sakurai
et al., 2004; Yousem, 2009). The multiple locations may have
therapeutic implications if peripheral and central LSCC have a
different cells of origin and, therefore, different growth patterns.
Trachea, mainstem bronchi, and the most proximal region of
the intralobular airway are lined by a pseudostratified columnar
epithelium composed of Basal, Ciliated, Neuroendocrine, and
Club secretory cells. Basal cells serve as tissue-specific stem
cells for the tracheobronchial compartment, since they can
both self-renew and give rise to Club and ciliated epithelial cells
(Hong et al., 2004; Rock et al., 2009). They express high levels of
the transcription factor p63, which is required for development of
the trachea (Daniely et al., 2004), and cytokeratin 5 (K5) and 14
(K14). Their expression profile (p63, K5) and their stem cell prop-
erties make them a likely candidate for the cell of origin of LSCC.
Club cells are more abundant and line the bronchi and bronchi-
oles. They can both self-renew and generate ciliated cells both
under homeostatic conditions and in response to epithelial injury
(Rawlins et al., 2009). The most distal region of the lung is orga-
nized into a complex system of alveoli, composed of alveolar520 Cancer Cell 30, 519–532, October 10, 2016type 1 (AT1) and 2 (AT2) cells. The latter are considered to be
the major stem cells of the alveolar epithelium, based upon their
ability to self-renew and give rise to AT1 cells (Adamson and
Bowden, 1974; Evans et al., 1975). Club cells and AT2 cells are
both indicated as cells of origin of lung LADC (Sutherland
et al., 2014). In this study, we define the impact of the cell of
origin on LSCC development.
RESULTS
Targeted Introduction of LSCC Recurrent Aberrations
by Recombinant Adenoviral Vectors
We have previously described a series of adenoviral vectors that
drive Cre-recombinase to Club and AT2 cells in the adult mouse
lung and have demonstrated that they are robust tools for the
assessment of the cell of origin of lung cancer (Sutherland
et al., 2011, 2014). We applied this same approach to target
basal progenitor cells. We utilized the promoter region of K14
or K5 to direct Cre-recombinase to basal progenitor cells (see
Supplemental Experimental Procedures for details).
To assess the specificity and efficiency of Ad5-K14-Cre and
Ad5-K5-Cre, we infected primary keratinocytes and mouse
embryonic fibroblasts (MEFs) isolated from mT/mG mice, a Cre
reporter mouse strain that expresses Tomato (mT) prior to Cre-
mediated excision and membrane-targeted GFP (mG) upon
excision (Muzumdar et al., 2007) (Figures S1A and S1B). Both
Ad5-K14-Cre and Ad5-K5-Cre efficiently delivered and activated
Cre-recombinase expression in keratinocytes, as indicated by
GFP expression (Figure S1A), but not in MEFs (Figure S1B).
We used Ad5-CMV-Cre as positive control of infection and
Ad5-SPC-Cre (Sutherland et al., 2011) as negative control, since
the promoter of SPC drives Cre expression only in AT2 cells. The
result was confirmed by western blot analysis (Figure S1C).
To validate the specificity of adenovirus promoter targeting
in vivo, we intratracheally injected mT/mG mice with a high titer
of either Ad5-K14-Cre or Ad5-K5-Cre, and performed GFP stain-
ing on trachea and lungs collected 3 weeks after infection to
identify switched cells.mT/mGmice were pretreated with naph-
thalene, which depletes Club secretory cells (Hong et al., 2004),
facilitating the access to tracheobronchial basal cells. Indeed,
GFP staining of tracheas isolated from mT/mG mice treated
with corn oil (vehicle control) was negative (Figure 1A), indicating
that under steady-state conditions the tracheobronchial epithe-
lium is relatively refractory to adenoviral infection. This is also the
case when Cre is under the direction of the cytomegalovirus
(CMV) promoter (Figure 1A). In stark contrast, however, Ad5-
CMV-Cre, Ad5-K14, and Ad5-K5-Cre showed a high level of
infection of basal cells when injected following naphthalene
administration (Figure 1A). In the lung, Cre-recombinase-medi-
ated switching occurred in the alveolar compartment of mice in-
tratracheally injected with Ad5-CMV-Cre, regardless whether
they were pretreated with naphthalene or corn oil (Figure 1B).
Ad5-K5-Cre and Ad5-K14-Crewere not able to drive Cre expres-
sion in any of the peripheral lung cell populations when pre-
treated with corn oil (Figure 1B), while naphthalene treatment
gave rise to a readily detectable population of switched cells
along the bronchial lumen (Figure 1B).
To demonstrate that GFP was specifically expressed by
basal cells, we performed dual immunofluorescence (IF)
Figure 1. In Vivo Characterization of Basal
Cell-Specific Adenoviral Vectors Using
mT/mG Reporter Mice
GFP IHC staining of longitudinal sections of tra-
cheas (A) and lungs (B) isolated from mT/mG re-
porter mice 3 weeks after intratracheal injection of
Ad5-CMV-Cre, Ad5-K14-Cre, and Ad5-K5-Cre
following pretreatment with corn oil or naphtha-
lene as indicated. Scale bars, 100 mm (A) and
200 mm (B). Scale bars in insets, 50 mm (B). See
also Figure S1.staining for GFP and K14, K5, or CC10 on tracheal sections
collected at 7 days after intratracheal injection of either Ad5-
K14-Cre or Ad5-K5-Cre in mice previously treated with naph-
thalene (Figure S1D). The co-expression of GFP with both
K14 and K5, but not CC10, indicated that Cre is specifically
activated in basal cells (Figure S1D). At 21 days the GFP stain-
ing was also found in cells overlaying the basal cells, consis-
tent with prior lineage-tracing experiments (Hong et al., 2004;
Rock et al., 2009) (Figure S1E). GFP staining on trachea
and lungs of mT/mG mice collected 2, 4, 6, 8, and 15 months
after virus injection upon naphthalene treatment indicated
that the specificity is retained over an extended period of
time (Figure S1F). We analyzed 11 mT/mG mice, which did
not show any neoplastic lesions, indicating that naphthalene
does not induce tumors. Taken together, our data indicate
that Ad5-K14-Cre and Ad5-K5-Cre efficiently and specifically
target tracheobronchial basal cells following naphthalene
treatment.
To recapitulate the genomic complexity of LSCC, we devel-
oped amouse model of LSCC based on the deregulation of mul-
tiple pathways involved in LSCC initiation and progression. We
generated compound conditional mutant mice for: (1) overex-
pression of SOX2, a transcription factor involved in squamous
differentiation by suppressing the Notch pathway and whoseCancgene is one of the most frequently ampli-
fied in SCC; (2) overexpression of FGFR1,
a tyrosine kinase receptor overexpressed
in 27% of LSCC cases and as such a
possible therapeutic target; (3) deletion
of PTEN, which encodes a phosphatase
that antagonizes the PI3K signaling
pathway and found to be altered in 24%
of LSCC cases; and (4) deletion of
the CDKN2AB locus that encodes for
p16INK4A, p15INK4B, and p14ARF, three
cell-cycle inhibitors with a well-estab-
lished tumor-suppressor function and in-
activated in 72% of LSCC cases (Cancer
Genome Atlas Research Network, 2012).
In the absence of p16INK4A, p15INK4B can
provide a backup function, thereby miti-
gating the effects of p16INK4A loss (Krim-
penfort et al., 2007). Consequently, loss
of both CDKN2A and CDKN2B has
more profound effects and is likely the
reason why both are often co-deletedin LSCC. These genetic alterations collectively cover a large
fraction of the human cases (Figure 2A).
Mice carrying the conditional allele of either Pten (Ptenflox/flox)
or Cdkn2ab have been previously generated in our laboratory
(Krimpenfort et al., 2007; Marino et al., 2002). Therefore, we
generated mice carrying the combined conditional deletions of
Pten and Cdkn2ab (hereafter PC mice). PC mice were crossed
to mT/mG reporter mice to identify cells in which the alleles
were actually recombined. To determine whether their inactiva-
tion in basal cells is sufficient to induce LSCC, we intratracheally
injected 6- to 8-week-old PC mice with either Ad5-K14-Cre or
Ad5-K5-Cre following naphthalene treatment (Figure 2B). Mice
were euthanized when they started to show signs of disease
(e.g., shortness of breath, weight loss), and trachea and lungs
were sampled for histopathological analysis.PCmice developed
tumors with a latency of 10–15 months and a frequency of 55%
(Table S1). The penetrance was calculated by scoring the mice
based on GFP staining. Mice negative for GFP staining were
not included because this would imply the absence of recombi-
nation. At 6 or 9 months the penetrance was very low (1/7 and
1/9, respectively). At 10–15 months tumor penetrance increased
(10/19; Table S1) and a wide spectrum of tumor lesions was
found (Figure 2C and Table S1). No obvious differences between
Ad5-K14-Cre- or Ad5-K5-Cre-injected PC mice were found.er Cell 30, 519–532, October 10, 2016 521
Figure 2. Generation of Mouse Models that
Recapitulate the Genomic Complexity of
Human LSCC
(A)Genetic alterationsofCDKN2A,CDKN2B,PTEN,
FGFR1, and SOX2 in the 178 human LSCC speci-
mens in the TCGA dataset. Exon skipping and DNA
methylation for the CDKN2A locus are excluded.
(B) Schematic representation of the experimental
design used for all cohorts of mice: PC, Fgfr1PC,
and Sox2PC. Mice are treated with naphthalene
on day 0 and intratracheally injected with Ad5-
K14-Cre or Ad5-K5-Cre on day 3.
(C) Representative H&E staining on various lung
lesions of PC mice. Scale bars, 100 mm.
See also Table S1.Taken together, these data demonstrated that tracheobronchial
basal cells can be efficiently transformed by loss of Pten and
Cdkn2ab, giving rise to a variety of tumors.
FGFR1 Overexpression Causes Neoplasia with Sporadic
Squamous Differentiation
To directly test the consequences of overexpressing fibroblast
growth factor receptor 1 (FGFR1) in vivo, we targeted a bicis-
tronic cDNA cassette containing a mutant active form of
FGFR1 (K656E) and the YFP to the Col1a1 locus (Figure S2A).
Validation of the recombinant event in embryonic stem cells
(ESCs) is described in Supplemental Experimental Procedures
and in Figures S2B and S2C. We crossed LSL-Fgfr1K656E mice
with PCmice and withmT/mG reporter mice (hereafter Fgfr1PC;
Figure 3A). Fgfr1PCmice pretreated with naphthalene and intra-
tracheally injected with either Ad5-K14-Cre or Ad5-K5-Cre
developed tumors with a latency of 1.5–6.5 months and a fre-
quency of 76% (16/21; Table S1).
Weobservedbronchoalveolar adenoma, polyp-like spindle cell
neoplasia, ADC, chondroid sarcoma, adenofibroma, and osteo-
sarcoma (FigureS2DandTableS1). In a fewcasessporadic squa-
mous cell differentiation was observed within the heterogeneous
lesion (19%; Figure 3 and Table S1). In general, tumorswere inva-
sive anddidclearly arise fromthebronchial lining (FigureS2D). Le-
sionscontaining squamousdifferentiationwerearrangedasnests
of cells in circular structures (Figures 3B and 3C) strongly positive
for K5 (Figure 3D). Immunohistochemistry (IHC) analysis showed522 Cancer Cell 30, 519–532, October 10, 2016that the lesions were positive for GFP
and FGFR1, as expected (Figures 3E and
3F); however, they were negative for p63
(Figure 3G). Taken together, our results
indicate that FGFR1 overexpression
transforms Pten- and Cdkn2ab-deficient
tracheobronchial basal cells at a higher
frequency and at a faster rate. Tumors
are heterogeneous with only sporadic
squamous differentiation.
SOX2 Serves as a Critical Switch
to Drive Heterogeneous Lesions
into LSCC
To overexpress SOX2 in vivo, we used an
approach similar to that described abovefor FGFR1 using cDNA for mouse SOX2 and CFP (Figure S2A).
Successful targeting of ESCs and expression of LSL-Sox2 allele
in vivo are described in Supplemental Experimental Procedures
and Figures S2B, S2C, and S2E. We crossed LSL-Sox2 mice
with PCmice, and withmT/mG reporter mice (hereafter Sox2PC;
Figure 4A). Seven to nine months after basal cell virus inocula-
tion, 73% of Sox2PCmice developed multiple LSCC that ranged
from moderately to well differentiated (Figure 4 and Table S1).
The large tumors expanded in the alveolar compartment (Fig-
ure 4B). Squamous cell differentiation was evident from the ker-
atin pearls and the prominent cornification in advanced lesions
(Figure 4B). The cornification was accompanied by infiltration
of inflammatory cells and large areas of necrosis. LSCC was
morphologically characterized by irregular nests or large nodules
(Figure 4C). In some cases, although the squamous cell differen-
tiation was predominant, small areas of ductal/glandular/
mucinous differentiations were observed (data not shown).
Twelve cases of human LSCCs were selected for a compara-
tive study of the Sox2PCmouse model. The selected cases dis-
played a wide spectrum of differentiation features of LSCCs,
from well-differentiated carcinomas showing a pavement-like
arrangement of cells with keratinization (Figure 4D) to poorly
differentiated carcinomas with comedo-like necrosis. Impor-
tantly, 11 of the 12 cases of human tumors expressed SOX2 (Fig-
ure 4E and Table S2). All human cases showed positive IHC for
p63 but were negative for TTF-1, a marker used to distinguish
LSCC from LADC (Figure 4E and Table S2). In line with this,
Figure 3. Combined Overexpression of
FGFR1 Partially Drives Squamous Differen-
tiation within Heterogeneous Neoplastic
Lesions
(A) Schematic representation of the Col1a1 locus
targeted with LSL-Fgfr1K656E transgene before
Cre infection. Fgfr1PC mice were infected with
basal specific adenoviruses.
(B and C) H&E staining of lung sections showing
squamous differentiation with nest of cells with
evident intercellular bridges (arrow in B) in circular
arrangement (C).
(D–G) IHC analysis of lung sections possessing
tumors with squamous differentiation, for K5 (D),
GFP (E), FGFR1 (F), and p63 (G).
Scale bars, 10 mm (B) and 50 mm (C–G). See also
Figure S2 and Table S1.Sox2PC mouse lesions showed positive staining for SOX2 and
p63 and were negative for TTF-1 (Figure 4E and Table S2). We
performed GFP staining to confirm that LSCC arose from cells
that had switched the conditional alleles (Figure 4F). GFP stain-
ing strongly overlapped with K14 and K5 staining (Figure 4F).
In the remaining 27% of cases, Sox2PC mice showed lesions
of atypical hyperplasia commonly in bronchi (Figure S3A), but
also in proximal and distal bronchioles, as indicated by GFP
staining (Figures S3A and S3B; Table S1). They were positive
for GFP, SOX2, K5, and to a lesser extent p63, indicative of the
early commitment toward squamous differentiation (Figure S3B).
We performed histological examination of all organs and
tissues for six Sox2PC mice to identify putative metastasis. We
observed SCC in the left atrium of the heart only in one case (Fig-
ure S3C). In the samemousewe found large lesions of SCC in the
anterior part of the nasal cavity (Figure S3D).
We also measured the RNA expression level of the endoge-
nous and exogenous SOX2 in the tumor area by performing
real-time RT-PCR analysis using oligonucleotide primers an-
nealed with the 30 UTR (Sox2 end) and with the IRES (SOX2
exo). LSCC isolated from Sox2PCmice showed high expression
of the exogenous SOX2, whereas the endogenous form was un-
detectable (Figure 4G). We used as control LADC samples iso-
lated from Kras;p53 mice and PC mice, where we could only
detect a low level of endogenous Sox2 expression (Figure 4G).
The levels of SOX2 expression were an order of magnitude
higher than what we could observe in LSL-Sox2;CreERT2
MEFs upon tamoxifen treatment (Figure 4H). As described
above, combined Pten and Cdkn2ab loss gives rise to heteroge-
neous neoplastic lesions; however, in Sox2PC mice none of
these heterogeneous lesions were found. These data indicate
that SOX2 overexpression drives a homogeneous LSCC pheno-Canctype resembling the histopathological
marker profile and the morphology of
the human counterpart.
An Epidermal Transcription
Program Differentiates Human and
Mouse LSCC from LADC
To molecularly characterize our mouse
model in an unbiased manner, we per-formedgenome-wide transcriptional analysis of LSCCofSox2PC
(LSCC) mice and LADC of Kras;p53 mice with and without
Eed (Kras;p53±Eed). Initially, we compared the mouse transcrip-
tional landscapes of six Sox2PC LSCC with those of eight
Kras;p53±Eed LADC. In parallel, the gene expression profiles of
18humanLSCCwithSOX2amplificationandCDKN2ABdeletion,
with or without PTEN deletion from the TCGA dataset (Cancer
Genome Atlas Research Network, 2012), were compared with
17 human primary LADC (Cancer Genome Atlas Research
Network, 2014) (Table S3) to generate a list of genotype-specific
LSCC genes. We identified 3,167 differentially expressed (DE)
genes between human LSCC and LADC by applying a log2
(fold change) of R ±1 and a false discovery rate of %0.05. Of
these, 1,599 genes were upregulated in LSCC tumors and
1,568 were downregulated. A comparison between Sox2PC and
Kras;p53±Eed tumor cells yielded 7,812 DE genes, of which
5,208 were upregulated and 2,604 downregulated. Importantly,
679 genes were DE genes in both species (518 upregulated and
161 downregulated; Figures 5A and S4A). Gene set enrichment
analysis (GSEA) showed a correlation between genes that typify
LSCC in mouse and human over LADC (Figures 5B and 5C).
Among thesharedupregulatedgenes,geneontology (GO)anal-
ysis revealed enrichment for 140 genes implicated in squamous
differentiation (p = 1.663 106), including SOX2, TP63,NOTCH3,
and several keratins involved in squamous carcinoma (KRT14,
KRT6B,KRT16,KRT84, andKRT4) (Figure 5D). Themost enriched
molecular functions were linked to metalloendopeptidases and
proteases, a hallmark of epidermal cells (Figure 5E). The most en-
riched GO categories were associated with cellular components
transcriptionally regulated by p63, such as cell adhesion and, in
particular, desmosomes (Figure 5F). Metalloendopeptidase
genes included Klk10 and Adam17, and protease genes includeder Cell 30, 519–532, October 10, 2016 523
Figure 4. SOX2 Promotes the Switch
from Heterogeneous Neoplastic Lesions to
Typical LSCC
(A) Schematic representation of the Col1a1 locus
targeted with LSL-Sox2 transgene before Cre
infection. Sox2PC mice were generated and in-
fected with basal specific adenoviruses.
(B and C) H&E staining on mouse lung sections
collected 7–9 months after injection. The tumor
showedprominent cornification (arrow inB), keratin
pearls, and inflammatory infiltration (arrows in C).
(D) H&E staining of well-differentiated human
LSCC.
(E) IHC staining on human and mouse lung sec-
tions with the indicated histopathological markers.
(F) IHC staining for GFP, K14, and K5 on mouse
lung sections.
(G and H) Real-time RT-PCR of Sox2 endogenous
(Sox2 end) and exogenous (SOX2 exo) levels
performed on tumor tissues isolated from the
indicated mouse tumor samples (G) and MEFs
untreated (UNT) or treated with tamoxifen (TAM)
(H). Data represent means ± SD. Samples are
normalized by using actin RNA level.
Scale bars, 200 mm (B) and 50 mm (C–F). See also
Figures S2 and S3; Tables S1 and S2.Tmprss11d (Figure5G),whoseRNA levelswereconfirmedby real-
time RT-PCR to discriminate mouse LSCC (Sox2PC) and LADC
(Kras;p53). We also confirmed the differential expression of
Dsg3 that encodes an important component of desmosomes (Fig-524 Cancer Cell 30, 519–532, October 10, 2016ure 5G). Desmosomal components found
to be upregulated in Sox2PC tumors
included direct p63 target genes such as
Dsg1 andDsc3 (Ferone et al., 2013). Other
p63 direct targets such as Fgfr2 and Irf6,
with an important role in the homeostasis
of squamous epithelia but deregulated in
the presence of p63 mutations (Ferone
et al., 2012; Thomason et al., 2010), were
also upregulated (Figure 5D).
As a complementary subtype assign-
ment, we compared our mouse LSCC
gene expression data with the four previ-
ously identified LSCC subtypes (Wilker-
son et al., 2010). Gene sets specific for
each subtype including basal, primitive,
classical, and secretory were obtained
fromWu et al. (2013). LSCC from Sox2PC
mice was enriched for all four subtypes
(Figure S4B). Taken together, our results
indicate that a p63-mediated epidermal
transcriptional program distinguishes hu-
man and mouse LSCC from their spe-
cies-matched LADC counterpart.
Tumor Microenvironment in the
Development of LSCC
Inflammatory infiltrates were marginal in
PC and Fgfr1PC mice compared withSox2PC mice, where large areas of neutrophil infiltrations were
clearly evident at histology (Figure 4B). Interestingly, we found
a sharp distinction between Sox2PC and PC or Fgfr1PC mice
with respect to the presence of tumor-associated macrophages
(TAMs) and tumor-associated neutrophils (TANs), the two major
components of tumor inflammatory infiltrates (Murdoch et al.,
2008). IHC analysis showed that TANs were abundantly present
in LSCCofSox2PCmice, as indicated by the expression of LY6G
(Figure 6A and Table S4) (Xu et al., 2014). To confirm this result,
we performed IHC analysis with antibodies against myeloperox-
idase (MPO). MPO is an antimicrobial enzyme most abundantly
expressed by TANs compared with naive neutrophils (Youn
et al., 2012) and, as expected, was overly present in the tumor
lesions of Sox2PC mice (Figure 6A). TAMs, identified by F4/80,
were poorly represented in LSCC lesions of Sox2PC mice as
compared with TANs (Figure 6A). Conversely, in the heteroge-
neous lesions of PCmice TANs were completely absent as indi-
cated by the negative staining for LY6G and MPO (Figure 6A),
whereas TAMs were the only inflammatory infiltrate found (Fig-
ure 6A). Surprisingly the squamous lesions of Fgfr1PC mice
were also negative for LY6G and MPO (Figure 6A), in favor of a
role for SOX2 in the activation of TANs. However, they showed
low-level expression of F4/80 (Figure 6A), indicative of TAMs.
We then focused on the analysis of immune populations pre-
sent in LSCC of Sox2PC mice compared with human LSCC.
The neutrophil infiltrations were present in all cases of human
LSCC analyzed (Table S4). Moreover, we found a striking similar-
ity in the highly immunogenic environment present in both spe-
cies, as indicated by CD4- and CD8-positive infiltrating cells,
which were readily observed in tumor stroma and tumor nests
of both species (Figure 6B and Table S4). HIF1-a, a transcrip-
tional regulator of cellular response to hypoxia, was detected
to various extents in the tumor cells of both human and mouse
LSCC (Figure 6B and Table S4). Interestingly we also found a
high level of PD-L1 expression, which showed membranous
staining in tumor cells of both human and mouse LSCC (Fig-
ure 6B and Table S4), although the percentage of positive cells
in human varied from 0.5% to 80% (Table S4). PD-1, the receptor
of PD-L1, was mainly observed in clusters of immune cells in
tumor stroma (Figure 6B and Table S4). No differences were
detected between peripheral or central LSCC (Table S4).
Sox2PC Mice Develop Peripheral LSCC when AT2 or
Club Cells Are Targeted
To investigate whether other cell types can serve as the cell
of origin of LSCC, we targeted Club and AT2 cells of Sox2PC
mice. We employed the promoter region of the mouse Cc10
that is expressed by tracheal and bronchiolar Club cells,
including bronchoalveolar stem cells (BASCs) (Kim et al., 2005)
and the promoter region of the mouse Surfactant Protein C
gene (Spc) that is expressed by AT2 cells present in the alveoli
and by BASCs.We injected 6- to 8-week-old Sox2PCmice intra-
tracheally with either Ad5-CC10-Cre or Ad5-SPC-Cre (Suther-
land et al., 2011). Strikingly, all mice developed tumors around
7–8 months after Cre activation, which were well to moderately
differentiated LSCC in more than 90% of cases (Figure S5A
and Table S5). Histologically, these tumors showed the hall-
marks of LSCC differentiation such as keratin pearls, cornifica-
tion, necrosis, and inflammation (Figure S5A) and were positive
for SOX2, p63, and K5 and negative for TTF-1 (Figure S5B and
Table S2). The early lesions were detected by GFP staining,
which overlapped with SOX2 and to a lesser extent with K5
and p63 (Figure S5C).Although the histopathological profiles were perfectly overlap-
ping, the size, number, and location of the lesions differed be-
tween the two groups. The number of carcinomas versus early le-
sions was substantially higher in Ad5-CC10-Cre-injected mice
compared with Ad5-SPC-Cre (Figure 7A). The difference was
found to be significant by a two-way ANOVA test (Figure 7B).
This finding indicates that only a subset of early lesions originating
fromAT2 cells progresses to LSCC,whereas this process ismore
efficientwhenClubcells are targeted.Singlecells or small clusters
of switchedcells in the alveolar compartment of Ad5-SPC-Cre-in-
jected mice were also found to be positive for CC10 as indicated
by the dual GFP-CC10 IF (Figure 7C and Table S5), and might
represent the previously described subpopulation of AT2 cells ex-
pressing a low level of CC10 (Rawlins et al., 2009). When mice
were injected with Ad5-CC10-Cre, switched single cells or small
clusters were often observed in bronchioles (Figure 7C), at the
bronchoalveolar duct junctions (BADJ) and in few cases also in
the alveolar compartment (data not shown), where a subpopula-
tion of AT2 cells expressing a low level of CC10 was noted (Raw-
lins et al., 2009). Early lesions of either injection in mice strongly
retained CC10 expression, as showed by GFP-CC10 dual IF
(Figure 7D) and, in the case of Ad5-SPC-Cre-injected mice, lost
the expression of SPC while progressing, as indicated by SPC-
CC10dual IF (Figure7DandTableS5).Duringprogression of early
lesions to carcinoma, the expression of CC10 is replaced by K5,
the two cell markers being mutually exclusively expressed in the
lesions of both Ad5-SPC-Cre- and Ad5-CC10-Cre-injected mice
(Figure 7E and Table S5). The transition of CC10+ to K5+ cells is
complete in advanced LSCC of both Ad5-SPC-Cre- and Ad5-
CC10-Cre-injected mice (Figure 7F). Taken together, our data
indicate that SOX2 overexpression in combination with Pten and
Cdkn2ab deletion is able to drive AT2 and Club cells toward
LSCC.Tumorprogression is clearlymore efficientwhenClub cells
are targeted. Inbothsituations the locationof the lesions isperiph-
eral, resembling the human peripheral subtype of LSCC.
By comparing the tumor-free survival of PCmice with Fgfr1PC
and Sox2PC mice, injected with Ad5-K14-Cre, we found that
both FGFR1 and SOX2 are able to accelerate tumor onset (Fig-
ure 8A and Table S1). The tumor-free survivals of Sox2PC
mice injected with Ad5-K14-Cre, Ad5-SPC-Cre, or Ad5-CC10-
Cre are comparable, ranging between 7 and 9 months. In our
model, Pten and Cdkn2ab deletion provides basal cells with
the capability to transform in multiple heterogeneous lesions.
FGFR1 overexpression accelerates tumorigenesis without
imposing a particular differentiation pattern, resulting only in oc-
casional squamous differentiation. In contrast, SOX2 overex-
pression remarkably imposes a squamous phenotype to Basal,
Club, and AT2 cells (Figure 8B).
Early lesions arise in bronchi and bronchioles when Sox2PC
mice are injected with Ad5-K14-Cre; bronchioles, BADJ, and,
to a lesser extent, alveolar space when they are injected with
Ad5-CC10-Cre, and BADJ and alveolar space when injected
with Ad-SPC-Cre (upper panel, Figure 8C). The morphology of
LSCC originating from different cells is identical, but the location
is in line with the different cell of origin (lower panel, Figure 8C).
We performed RNA-sequencing (RNA-seq) analysis and
compared the gene expression profiles of Basal-, AT2-, and
Club-derived LSCC. Our analysis revealed a strong correlation
between their expression profiles, with only 60 genes found toCancer Cell 30, 519–532, October 10, 2016 525
Figure 5. Gene Expression Profile Analysis
(A) Venn diagram showing the commonly DE genes betweenmouse and human LSCC found by comparing DE genes between Sox2PC versusKras;p53±Eed and
human LSCC versus LADC.
(B and C) GSEA for genes upregulated in Sox2PC (B) and hLSCC (C) compared with Kras;p53±Eed and hLADC, respectively.
(D) Hierarchical clustering of upregulated genes in both mouse and human LSCC, which are enriched for a squamous differentiation signature.
(legend continued on next page)
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Figure 6. Tumor Microenvironment in the Three Cohorts of Mice and Comparative Analysis of Human and Mouse LSCC
(A) IHC analysis performed on adult lung tissues of Sox2PC, PC, and Fgfr1PC mice, using the indicated antibodies against markers of inflammatory cells.
(B) IHC analysis performed on human and mouse LSCC for the indicated markers of immune cells.
Scale bars, 200 mm (A) and 50 mm (B). Scale bars in insets, 50 mm (A). See also Table S4.be DE in AT2-derived LSCC versus Basal-derived LSCC, and as
little as 28 differentially expressed genes in Club-derived LSCC
versus Basal-derived LSCC (Figure 8D and data not shown).
These results suggest that enforced expression of SOX2, rather
than the cell of origin, dictates the resulting tumor phenotype.We
suggest that human peripheral LSCC might also arise from pe-
ripheral SPC and CC10 expressing cells.
DISCUSSION
In this study we demonstrate that Pten- and Cdkn2ab-deficient
tracheobronchial basal cells can be efficiently transformed into a(E and F) Significant GO categories for molecular functions (E) and cellular comp
(G) Real-time RT-PCR of the indicated genes performed on tumor tissues isola
Samples are normalized by using actin RNA level.
See also Figure S4 and Table S3.variety of lung tumors. The additional overexpression of SOX2,
but not FGFR1, results in a homogeneous LSCC phenotype
closely resembling the human counterpart. Genome-wide tran-
scriptional profiles of tumors from Sox2PC and Kras;p53±Eed
mice revealed the differential regulation of gene categories that
typify human LSCC over LADC, indicating that SOX2 imposes
squamousdifferentiationmost likely by activating a p63-mediated
transcriptional epithelial program.Critically, SOX2overexpression
is also able to impose an LSCC phenotype to Club and AT2 cells,
indicating the potency of SOX2 in directing transdifferentiation.
The gene promoters we used to target basal cells are already
well described as recapitulating the gene expression of K5 andonents (F).
ted from the indicated mouse tumor samples. Data represent means ± SD.
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Figure 7. Club and AT2 Cells Are Trans-
formed to Give Rise to LSCC in Sox2PC
Mice
(A) Scan images of GFP staining performed on
lungs isolated from Sox2PCmice injected with the
indicated adenoviruses.
(B) Quantification of the comparison of early le-
sions versus carcinoma in Ad5-SPC-Cre- and
Ad5-CC10-Cre-injected mice (Ad-SPC-Cre, p <
0.0001; Ad5-CC10-Cre, p < 0.05). Data represent
means ± SD.
(C–F) Dual IF staining with the indicated markers,
performed on lung tissues isolated from Sox2PC
mice injected with the indicated adenoviruses,
representative of single/small clusters of targeted
cells (C), early lesions (D), intermediate lesions (E),
and advanced LSCC (F).
Scale bars, 20 mm (C, D) and 50 mm (E, F).
See also Figure S5 and Table S5.K14 (Jonkers et al., 2001; Ramirez et al., 2004), which are estab-
lished markers of basal cells of stratified (skin) and pseudostra-
tified epithelia (trachea). Nevertheless, loss of Pten andCdkn2ab
gave rise to a variety of tumors including sarcomas, osteomas,
and histiocytic lesions. IHC analysis for a panel of EMT markers
including E-cadherin (ECAD), keratin 8 (K8), and vimentin (VIM)
showed residual expression of ECAD and K8 in some mesen-
chymal lesions strongly expressing VIM. In other cases the
epithelial compartment co-existed with a distinct mesenchymal
compartment, pointing to the presence of multiple populations
of basal cells with different lineage commitments. The genotype
including Cdkn2ab deletion might play an important role in this
high plasticity, which becomes restricted to SCC only by forced
SOX2 expression.
Both SOX2 and FGFR1 are frequently amplified in LSCC, in
some cases in the absence of mutations in the CDKN2AB and
PTEN (Cancer Genome Atlas Research Network, 2012). This
led to the hypothesis that they are critical driver oncogenes in
this malignancy. Our data support a role for FGFR1 in acceler-
ating tumor development without forcing the cells toward a
particular tumor subtype. In contrast, SOX2 appears critical in
driving cells toward an aggressive and penetrant LSCC pheno-
type. It will be interesting to assess in future experiments
whether the combination of FGFR1 and SOX2 results in exclu-528 Cancer Cell 30, 519–532, October 10, 2016sive LSCC with a much shorter latency
period than observed with SOX2. It will
also be important to determine how
SOX2 amplification synergizes with aber-
rations in TP53 (cell cycle) and NFE2L2
(oxidative stress response) that are also
frequently observed in LSCC (Cancer
Genome Atlas Research Network, 2012).
The most remarkable feature of LSCC
is the amplification on chromosome
3q26 (Bass et al., 2009; Hussenet
et al., 2010; Tonon et al., 2005) where
both SOX2 and TP63 lie. More refined
genomic analyses have shown that
SOX2 is the focus of high-level amplifica-tions in lung and esophageal SCC (Bass et al., 2009; Liu et al.,
2013). SOX2 is actually amplified and/or overexpressed in 63%
of human LSCC (Cancer Genome Atlas Research Network,
2012) but 80%–90% of LSCC expresses SOX2 at the protein
level (Brcic et al., 2012; Sholl et al., 2010; Tsuta et al., 2011), sug-
gesting that multiple biological mechanisms can ensure its acti-
vation. The homogeneous LSCC phenotype ofSox2PCmice is in
line with this and suggests that human LSCC in which SOX2 is
not amplified might carry other driver mutations with a similar ef-
fect. The expression patterns of SOX2 and p63 clearly overlap;
both proteins showed heterogeneous staining. We showed
that this heterogeneity is maintained in both human and mouse
LSCC regardless of whether the location of the tumor is periph-
eral or central. Importantly, the co-expression with p63, a known
stem cell marker of stratified epithelia (Senoo et al., 2007), sug-
gests a critical role for SOX2-expressing cells in tumor mainte-
nance. This observation is in line with previous studies per-
formed on human skin SCC in which SOX2-expressing cells
marked cancer stem cells able to initiate and propagate the
tumor (Boumahdi et al., 2014). The transcriptional analysis of
LSCC from Sox2PC mice confirmed the strong interplay be-
tween p63 and SOX2. Further analysis, for example chromatin
immunoprecipitation sequencing using antibodies against either
p63 or SOX2 performed on early and late LSCC lesions from
Figure 8. FFGR1 and SOX2 Are Both Tumor
Drivers but Only SOX2 Imposes an LSCC
Phenotype
(A) Lung carcinoma-free survival curve of mice
with the indicated genotypes.
(B) Schematic representation of tumors arising in
mice with different genetic lesions, activated in
distinct lung cell types: LSCC arises from PCmice
following overexpression of SOX2 but not FGFR1.
Sox2PC mice develop LSCC also from AT2 and
Club cells.
(C) LSCC arises in different locations according to
the targeted cell population. Scale bars, 50 mm.
(D) Hierarchical clustering of transcriptional
profiling of the indicated Basal-, AT2-, and Club-
derived LSCC samples. One hundred genes with
the largest variability across samples were used.
Columns are for samples and rows are for genes.Sox2PC mice, could reveal the sequence of events driving the
development of LSCC.
We observed a highly immunogenic environment in both hu-
man and mouse LSCC. Tumor development is often associated
with the local accumulation of myeloid-derived suppressor cells
(MDSC), which represent a heterogeneous population of cells
including polymorphonuclear neutrophils, monocytes, macro-
phages,myeloid precursor cells, and dendritic cells, that support
tumor growth by suppressing anti-tumor T cell responses. Tu-
mor regression might be achieved by targeting MDSC in LSCC
(Chioda et al., 2011; Condamine and Gabrilovich, 2011; Filipazzi
et al., 2012; Youn and Gabrilovich, 2010; Youn et al., 2008).
Moreover, we found consistently high levels of PD-L1 in LSCC
of Sox2PC mice whereas in human LSCC its expression was
rather variable. This is not surprising, given the high complexityCancof human LSCC genome compared with
the Sox2PC mouse model in which mice
carry the same combination of genetic le-
sions. However, both human andSox2PC
mouse LSCC consistently express PD-1.
Since PD-L1 and PD-1 blockage is an
appealing cancer therapy (Zou et al.,
2016), the Sox2PCmouse is an appealing
model for the assessment of immuno-
therapeutic parameters.
In the LSCC model in which SOX2 was
delivered by intranasal lentivirus adminis-
tration on an Lkb1 null background, mice
developed tumors in 40% of cases and
this percentage included a few LADC
(Mukhopadhyay et al., 2014). In another
model in which SOX2 was overexpressed
in either AT2 or Club secretory cells, mice
developed well-differentiated LADC but
not LSCC (Lu et al., 2010).When targeting
AT2 and Club cells, Sox2PC mice exclu-
sively developed LSCC. These results
indicate that the context of SOX2 over-
expression with other cooperating muta-
tions is decisive in driving these differentcell types toward LSCC transformation. Despite the different
location RNA-seq data showed strong similarities, with only a
small number of genes being DE in LSCC arising from Club
and AT2 cells versus basal cells. In future experiments we will
address whether any of these can serve as a marker of the cell
of origin. Numerous early lesions do not progress to LSCC
when AT2 cells are targeted. Although the targeted cells were
primarily SPC-expressing cells, some of them also showed
CC10 expression. It is possible that the subpopulation of double
CC10+SPC+ cells described in the alveolar compartment and at
the BADJ (Rawlins et al., 2009) have served as the cell of origin of
LSCC when AT2 cells are targeted. The CC10+ lesions then
progress further, losing CC10 expression and acquiring squa-
mous markers. In a way we witness here the reverse transdiffer-
entiation as described earlier for conditional KrasG12D mice iner Cell 30, 519–532, October 10, 2016 529
which CC10 targeting resulted in the transdifferentiation of
SOX2+CC10+ cells toward SPC+ adenocarcinomas (Sutherland
et al., 2014). There is an ongoing debate about whether periph-
eral and central LSCC have different cells of origin, as this might
be associated with different responses toward therapy (Funai
et al., 2003; Hayashi et al., 2013; Sakurai et al., 2004; Yousem,
2009). Our results point to the likelihood that central and periph-
eral LSCC have different cells of origin but are otherwise very
similar.
In conclusion, we have generated a mouse model that repro-
duces the salient features of human LSCC, expressing a set of
LSCC-specific markers and showing infiltration by distinct sub-
sets of inflammatory cells. Since this mouse model is based on
the mutations frequently found in human LSCC, it is likely that
identical or, at least, very similar signaling pathways are involved.
This makes this model particularly valuable for exploring the ef-
fects of additional lesions and as a model to design and assess
the value of intervention strategies. Furthermore, the set of mu-
tations we used can impose both peripheral and central LSCC,
dependent on the cell types targeted. It will be interesting in
future experiments to investigate whether the LSCC retain any
molecular markers from their cell of origin and whether this pro-
vides new inroads for targeted therapies.
EXPERIMENTAL PROCEDURES
More detailed procedures can be found in Supplemental Experimental
Procedures.
Mouse Strains and Human Samples
All experiments involving animals were performed in accordance with Dutch
and European regulations on care and protection of laboratory animals and
have been approved by the local animal experiment committee at Netherlands
Cancer Institute, DEC NKI (OZP ID 12051). Mice were housed under standard
condition of feeding, light, and temperature, with free access to food and
water.
Ptenflox/flox (Marino et al., 2002), Cdkn2ab flox/flox (Krimpenfort et al., 2007),
Kras;p53±Eda (Jackson et al., 2001; Jonkers et al., 2001; Serresi et al.,
2016), and mT/mG (Muzumdar et al., 2007) mice have been previously
described. LSL-Sox2 and LSL-Fgfr1K656E mice were generated using the
Flp-RMCE technology (see Supplemental Experimental Procedures for de-
tails). All animals were maintained on an FVB background (backcrossed
from strains generated from 129 Ola ESCs).
We collected 12 primary LSCC resections from the archive of the pathology
department of the Antoni van Leeuwenhoek hospital. The study CFMPB459
entitled ‘‘Genomic and Immunohistochemistry Profiling of Human Squamous
Cell Carcinoma’’ has been reviewed and approved by the NKI Institutional Re-
view Board (IRB). The IRB approval procedure for ‘‘secondary use’’ of human
material is according to Dutch legislation (code of conduct). All tumor samples
were reviewed by at least two expert pathologists.
Intratracheal Adenovirus Instillation
Mice were treated with cyclosporine A (Novartis) orally in the drinking water,
1 week prior and 2–3 weeks following adenovirus injection. Three days
before the infection, mice were intraperitoneally injected with naphthalene
(250 mg/kg) or an equal amount of corn oil. On the fourth day they were intra-
tracheally injected with 20 mL of 13 1010 pfu/mL purified Ad5-K14-Cre or Ad5-
K5-Cre viruses (see Supplemental Experimental Procedures for details). Mice
injected with either Ad5-SPC-Cre or Ad5-CC10-Cre were only treated with
cyclosporine A 1 week prior to and 2–3 weeks following adenovirus injection.
Histology and Immunohistochemistry
For histological analysis, lungs were inflated and fixed for 24 hr with ethanol/
acetic acid/formalin (EAF). Trachea was collected separately and also fixed530 Cancer Cell 30, 519–532, October 10, 2016EAF. Fixed tissues were subsequently dehydrated and embedded in paraffin,
and sections of 2–4 mm were prepared and stained with H&E for subsequent
histopathological analyses. See Supplemental Experimental Procedures for
details of antibodies used for staining.
Gene Expression Profiling
The procedure is described in Supplemental Experimental Procedures.
ACCESSION NUMBERS
Sequencing data relative to tumors from Kras;p53±Eedmice are available un-
der accession number GEO: GSE61190. Sequencing data relative to tumors
from Sox2PC mice are available under accession number GEO: GSE78948.
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Supplemental Information includes Supplemental Experimental Procedures,
five figures, and five tables and can be found with this article online at http://
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